Advertisement

Topics

Phil Erlanger Research Co., Inc. Company Profile

12:35 EDT 22nd September 2018 | BioPortfolio

Welcome to Erlanger.com, a resource for investors seeking advanced technical analysis research and data. State-of-the-art computational techniques are combined with important, proprietary market data, enabling Phil Erlanger Research to offer independent, value-added data and analysis on over 6000 equity issues, 139 industry groups and 18 sectors. Following his experience as Advest 's Chief Technical Analyst, and his 5 year tenure as Senior Technical Analyst for Fidelity Management & Research Co. , Inc., Philip B. Erlanger formed his own company with the goal of providing high quality, unique information and research.

Location

Maynard
Massachusetts
United States of America


News Articles [67 Associated News Articles listed on BioPortfolio]

Erlanger Health System partners with Viz.ai to transform stroke care

Erlanger Health System, a multi-hospital health system based in Tennessee have announced a partnership with Viz.ai., a leading applied artificial intelligence company, to transform stroke care.

Zilliant Names Phil Fraher as Chief Financial Officer

"Phil has an excellent track record advising fast-growth organizations and we're excited to welcome him to the company," said Zilliant CEO Greg Peters. "I'm Read more...

Vertex Pharmaceuticals-Aktie: Konkurrenz hat das Nachsehen!

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Analyst Phil Nadeau von Cowen and Company: Phil Nadeau, Aktienanalyst von Cowen and Company, rechnet laut einer Aktienanalys...

Viz.ai and Erlanger Health System Partner to Bring Innovative Artificial Intelligence to Stroke Care

Erlanger Health System, a multi-hospital health system based in Tennessee have announced a partnership with Viz.ai., a leading applied artificial intelligence company, to transfor...

Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR-T Manufacturing Process in Cell & Gene Therapy

Cesca Therapeutics (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of the Com...

Illumina Picks Genomic Health’s Phil Febbo for Chief Medical Officer

Illumina (NASDAQ: ILMN) has appointed Phil Febbo to serve as chief medical officer of the San Diego genomics technologies company. Febbo most recently worked as chief medical officer of Redwood City, ...

Man flaunts incredible transformation after dropping 10 STONE in a year after a bet with co-worker – Scottish Daily Record

Scottish Daily RecordMan flaunts incredible transformation after dropping 10 STONE in a year after a bet with co-workerScottish Daily RecordPhil Hulton weighed a massive 25-stone at his worst, but man...

Dr Phil Jones to join BioAscent as new CSO

PubMed Articles [607 Associated PubMed Articles listed on BioPortfolio]

Treatment of post-traumatic joint contracture in a rabbit model using pulsed, high intensity laser and ultrasound.

Post-traumatic joint contracture induced by scar tissues following a surgery or injury can leave patients in a permanent state of pain and disability, which is difficult to resolve by current treatmen...

Increasing Residency Research Output While Cultivating Community Research Collaborations.

Having a research curriculum in addition to hosting a resident research day stimulates research activity in residency programs. Research collaborations outside an individual residency program may also...

Research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust.

Meta-research is research about research. Meta-research may not be as click-worthy as a meta-pug-a pug dog dressed up in a pug costume-but it is crucial to understanding research. A particularly valua...

A consensus statement on how to conduct inclusive health research.

The active involvement of people with intellectual disabilities in research, or inclusive research, is relatively common. However, inclusive health research is less common, even though it is expected ...

UK's first NHS high-energy proton beam facility.

With the UK's first high-energy Proton Beam Therapy Centre set to open next year at Manchester's The Christie, young patients with head and neck tumours, cancers close to the skull or spine, or a vari...

Clinical Trials [1089 Associated Clinical Trials listed on BioPortfolio]

PHIL in the Treatment of Intracranial dAVF.

This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualify...

PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)

The primary objective of this study is to assess the efficacy and safety of PHIL® liquid embolic agent in endovascular embolization of cerebral arteriovenous malformations.

PHIL Evaluation in the Endovascular Treatment of Intracranial Dural AVF

The primary objective of this study is to demonstrate the safety and efficacy of the PHIL® liquid in endovascular treatment of dural arteriovenous fistula.

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian cancer may be caused by a build-up of genetic defects, or damaged genes within the cells of the body. Because the genes are damaged, the body is unable to produce a group of protei...

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian cancer may be caused by a build-up of genetic defects, or damaged genes within the body's cells. When genes are damaged, the body may be unable to produce a group of proteins, call...

Companies [1049 Associated Companies listed on BioPortfolio]

Phil Erlanger Research Co., Inc.

Welcome to Erlanger.com, a resource for investors seeking advanced technical analysis research and data. State-of-the-art computational techniques are combined with important, proprietary market data,...

Purple Heart Injury Laboratories

PHIL is a Defense Medicine™ incubator that supports the development of new technologies and therapies for healing battlefield injuries. PHIL’s objective is to become the...

Phil Inc.

Phil is an end-to-end prescription management service providing a convenient alternative to traditional pharmaceutical management. Through its desktop website and mobile app, Phil...

Phil Ellis Associates, Inc.

Phil Ellis Associates, Inc. is a professional search and recruiting firm specializing in the pharmaceutical, medical device, diagnostic, biomedical and allied industries and operates under the guidanc...

ValueMedics Research, LLC

Jonothan C. Tierce, C.Phil., and Elisabeth H. Hazard, Ph.D., formed ValueMedics in 2003. The initial staff was made up of the Health Economics, Outcomes Research, Pricing and Market Access unit of the...

More Information about "Phil Erlanger Research Co., Inc." on BioPortfolio

We have published hundreds of Phil Erlanger Research Co., Inc. news stories on BioPortfolio along with dozens of Phil Erlanger Research Co., Inc. Clinical Trials and PubMed Articles about Phil Erlanger Research Co., Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Phil Erlanger Research Co., Inc. Companies in our database. You can also find out about relevant Phil Erlanger Research Co., Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record